Miles Parkes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5490720/publications.pdf

Version: 2024-02-01

150 papers	43,837 citations	17776 65 h-index	12638 137 g-index
159 all docs	159 docs citations	159 times ranked	53193 citing authors

#	Article	IF	Citations
1	Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet. Gut, 2022, 71, 1821-1830.	6.1	63
2	How Do We Predict a Patientâ€™s Disease Course and Whether They Will Respond to Specific Treatments?. Gastroenterology, 2022, 162, 1383-1395.	0.6	31
3	Rectovaginal Fistula in Crohn's Disease: When and How to Operate?. Clinics in Colon and Rectal Surgery, 2022, 35, 010-020.	0.5	3
4	Establishment of a validated central reading system for ileocolonoscopy in an academic setting. Gut, 2022, 71, 661-664.	6.1	3
5	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. The Lancet Gastroenterology and Hepatology, 2022, 7, 342-352.	3.7	100
6	Single-cell genomics for resolution of conserved bacterial genes and mobile genetic elements of the human intestinal microbiota using flow cytometry. Gut Microbes, 2022, 14, 2029673.	4.3	5
7	A systems genomics approach to uncover patient-specific pathogenic pathways and proteins in ulcerative colitis. Nature Communications, 2022, 13, 2299.	5.8	9
8	Randomized Trial of Ciprofloxacin Doxycycline and Hydroxychloroquine Versus Budesonide in Active Crohnâ€™s Disease. Digestive Diseases and Sciences, 2021, 66, 2700-2711.	1.1	10
9	The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohnâ€™s Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation. Journal of Crohn's and Colitis, 2021, 15, 800-812.	0.6	22
10	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. The Lancet Gastroenterology and Hepatology, 2021, 6, 218-224.	3.7	111
11	A Crohnâ€™s Disease-associated IL2RA Enhancer Variant Determines the Balance of T Cell Immunity by Regulating Responsiveness to IL-2 Signalling. Journal of Crohn's and Colitis, 2021, 15, 2054-2065.	0.6	5
12	Moving towards more patient-centred clinical trials in IBD. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 673-674.	8.2	8
13	P100â€…Outcomes of a clinical psychology intervention in a UK IBD service. , 2021, , .		0
14	P156â€…The inflammatory bowel disease (IBD) bioresource: focus on the inception cohort. , 2021, , .		0
15	Enhanced neoplasia detection in chronic ulcerative colitis: the ENDCaP-C diagnostic accuracy study. Efficacy and Mechanism Evaluation, 2021, 8, 1-88.	0.9	0
16	Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohnâ€™s disease: long-term outcomes for 11â€‰928 patients in the UK inflammatory bowel disease bioresource. Gut, 2021, 70, 677-686.	6.1	41
17	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nature Genetics, 2021, 53, 1543-1552.	9.4	96
18	GWAS of stool frequency provides insights into gastrointestinal motility and irritable bowel syndrome. Cell Genomics, 2021, 1, 100069.	3.0	15

#	Article	IF	Citations
19	Dynamic immunoglobulin responses to gut bacteria during inflammatory bowel disease. Gut Microbes, 2020, 11, 405-420.	4.3	44
20	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohnâ€™s Disease. Gastroenterology, 2020, 158, 189-199.	0.6	249
21	Personalised medicine in Crohn's disease. The Lancet Gastroenterology and Hepatology, 2020, 5, 80-92.	3.7	55
22	Somatic Evolution in Non-neoplastic IBD-Affected Colon. Cell, 2020, 182, 672-684.e11.	13.5	122
23	Clinical Trials [and Tribulations]: The Immediate Effects of COVID-19 on IBD Clinical Research Activity in the UK. Journal of Crohn's and Colitis, 2020, 14, 1769-1776.	0.6	13
24	Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease. Nature Communications, 2020, 11, 995.	5.8	37
25	The Inflammatory Bowel Disease (IBD) BioResource: an open-access platform of over 25,000 patients to accelerate research in Crohn's and Colitis. Proceedings of the Nutrition Society, 2020, 79, .	0.4	0
26	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut, 2020, 69, 984-990.	6.1	232
27	Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience. Annals of Gastroenterology, 2020, 33, 170-177.	0.4	13
28	IDDF2020-ABS-0183â€…PROFILE trial: predicting outcomes for Crohnâ€™s disease using a molecular biomarker. , 2020, , .		0
29	IBD BioResource: an open-access platform of 25â€‰000 patients to accelerate research in Crohnâ€™s and Colitis. Gut, 2019, 68, 1537-1540.	6.1	25
30	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut, 2019, 68, s1-s106.	6.1	1,353
31	Autologous stem cell transplantation in refractory Crohnâ€™s disease â€“ low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. BMC Gastroenterology, 2019, 19, 82.	0.8	17
32	Genetic and Genomic Markers for Prognostication. , 2019, , 323-331.		0
33	Microscopic colitis. Medicine, 2019, 47, 388-390.	0.2	1
34	A blood-based prognostic biomarker in IBD. Gut, 2019, 68, 1386-1395.	6.1	132
35	Diverticular disease: picking pockets and population biobanks. Gut, 2019, 68, 769-770.	6.1	3
36	Anti-commensal IgG Drives Intestinal Inflammation and Type 17 Immunity in Ulcerative Colitis. Immunity, 2019, 50, 1099-1114.e10.	6.6	139

#	Article	IF	Citations
37	Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. The Lancet Gastroenterology and Hepatology, 2019, 4, 341-353.	3.7	431
38	Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open, 2019, 9, e023765.	0.8	25
39	Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 2019, 321, 773.	3.8	129
40	Mitochondrial neurogastrointestinal encephalopathy: a clinicopathological mimic of Crohnâ€™s disease. BMC Gastroenterology, 2019, 19, 11.	0.8	10
41	IBD Genomic Risk Loci and Overlap with Other Inflammatory Diseases. , 2019, , 91-115.		0
42	The Impact of NOD2 Variants on Fecal Microbiota in Crohnâ€™s Disease and Controls Without Gastrointestinal Disease. Inflammatory Bowel Diseases, 2018, 24, 583-592.	0.9	40
43	Acetarsol Suppositories: Effective Treatment for Refractory Proctitis in a Cohort of Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2018, 63, 1011-1015.	1.1	8
44	Patients with perianal Crohn's fistulas experience delays in accessing antiâ€<scp>TNF</scp> therapy due to slow recognition, diagnosis and integration of specialist services: lessons learned from three referral centres. Colorectal Disease, 2018, 20, 797-803.	0.7	11
45	NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease. Mucosal Immunology, 2018, 11, 562-574.	2.7	71
46	PWE-044â€...The IBD bioresource: progressing from genetics to function and clinical translation in CD & UC. , 2018, , .		0
47	PRedicting Outcomes For Crohnâ€™s dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial. BMJ Open, 2018, 8, e026767.	0.8	55
48	On the threshold of personalized medicine in inflammatory bowel disease: Next generation genetic predictors. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 5-6.	1.4	0
49	Debate session: So what causes inflammatory bowel disease? It's all in the genes. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 23-23.	1.4	0
50	Selectively targeting the gut in inflammatory bowel disease: Targeting integrins. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 26-26.	1.4	0
51	Predicting the Individual Risk of Acute Severe Colitis at Diagnosis. Journal of Crohn's and Colitis, 2017, 11, jjw159.	0.6	19
52	Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease. Nature Genetics, 2017, 49, 262-268.	9.4	250
53	Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nature Genetics, 2017, 49, 256-261.	9.4	943
54	Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. Nature Genetics, 2017, 49, 186-192.	9.4	153

#	Article	IF	Citations
55	Defective ATG16L1-mediated removal of IRE1Î± drives Crohnâ€™s diseaseâ€“like ileitis. Journal of Experimental Medicine, 2017, 214, 401-422.	4.2	141
56	Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. Alimentary Pharmacology and Therapeutics, 2017, 46, 150-161.	1.9	53
57	Fine-mapping inflammatory bowel disease loci to single-variant resolution. Nature, 2017, 547, 173-178.	13.7	473
58	Intestinal APCs of the endogenous nanomineral pathway fail to express PD-L1 in Crohnâ€™s disease. Scientific Reports, 2016, 6, 26747.	1.6	30
59	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. American Journal of Human Genetics, 2016, 98, 857-868.	2.6	21
60	Genome-wide rare copy number variation screening in ulcerative colitis identifies potential susceptibility loci. BMC Medical Genetics, 2016, 17, 26.	2.1	14
61	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 149-158.	0.6	85
62	Relapse after withdrawal from antiâ€‹scp›TNF‹/scp› therapy for inflammatory bowel disease: an observational study, plus systematic review and metaâ€‹analysis. Alimentary Pharmacology and Therapeutics, 2016, 43, 910-923.	1.9	87
63	Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nature Genetics, 2016, 48, 510-518.	9.4	617
64	Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet, The, 2016, 387, 156-167.	6.3	607
65	High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nature Genetics, 2015, 47, 172-179.	9.4	280
66	Disease-Specific Alterations in the Enteric Virome in Inflammatory Bowel Disease. Cell, 2015, 160, 447-460.	13.5	1,036
67	Pooled Sequencing of 531 Genes in Inflammatory Bowel Disease Identifies an Associated Rare Variant in BTNL2 and Implicates Other Immune Related Genes. PLoS Genetics, 2015, 11, e1004955.	1.5	59
68	Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nature Genetics, 2015, 47, 979-986.	9.4	1,965
69	Generation of primary human intestinal T cell transcriptomes reveals differential expression at genetic risk loci for immune-mediated disease. Gut, 2015, 64, 250-259.	6.1	30
70	Microscopic colitis. Medicine, 2015, 43, 291-292.	0.2	0
71	Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Alimentary Pharmacology and Therapeutics, 2014, 40, 1313-1323.	1.9	55
72	â€˜High definitionâ€™: not all it appears: TableÂ1. Gut, 2014, 63, 863.1-864.	6.1	1

#	Article	IF	Citations
73	A Comparison of Outcomes for Adults and Children Undergoing Resection for Inflammatory Bowel Disease: Is There a Difference?. ISRN Gastroenterology, 2014, 2014, 1-4.	1.5	9
74	HLA-DQA1â€“HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 2014, 46, 1131-1134.	9.4	165
75	Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nature Reviews Genetics, 2013, 14, 661-673.	7.7	459
76	Association Between Variants of PRDM1 and NDP52 and Crohn's Disease, Based on Exome Sequencing and Functional Studies. Gastroenterology, 2013, 145, 339-347.	0.6	149
77	Human SNP Links Differential Outcomes in Inflammatory and Infectious Disease to a FOXO3-Regulated Pathway. Cell, 2013, 155, 57-69.	13.5	200
78	Negligible impact of rare autoimmune-locus coding-region variants on missing heritability. Nature, 2013, 498, 232-235.	13.7	184
79	Deep Resequencing of GWAS Loci Identifies Rare Variants in CARD9, IL23R and RNF186 That Are Associated with Ulcerative Colitis. PLoS Genetics, 2013, 9, e1003723.	1.5	185
80	Personalised medicine and genetic prediction â€“ are we there yet?. Clinical Medicine, 2013, 13, s62-s64.	0.8	1
81	DNA Methylation Analysis in the Intestinal Epitheliumâ€”Effect of Cell Separation on Gene Expression and Methylation Profile. PLoS ONE, 2013, 8, e55636.	1.1	24
82	The Genetics of Crohnâ€™s Disease. , 2013, , 99-118.		0
83	Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry. Nature Genetics, 2012, 44, 3-5.	9.4	44
84	Bayesian refinement of association signals for 14 loci in 3 common diseases. Nature Genetics, 2012, 44, 1294-1301.	9.4	469
85	The Genetics Universe of Crohnâ€™s Disease and Ulcerative Colitis. Digestive Diseases, 2012, 30, 78-81.	0.8	25
86	Hostâ€“microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 2012, 491, 119-124.	13.7	4,038
87	Evidence from Genetics for a Role of Autophagy and Innate Immunity in IBD Pathogenesis. Digestive Diseases, 2012, 30, 330-333.	0.8	42
88	Mucosal genome-wide methylation changes in inflammatory bowel disease. Inflammatory Bowel Diseases, 2012, 18, 2128-2137.	0.9	135
89	Immuno-inhibitory PD-L1 can be induced by a Peptidoglycan/NOD2 mediated pathway in primary monocytic cells and is deficient in Crohn's patients with homozygous NOD2 mutations.. Clinical Immunology, 2012, 143, 162-169.	1.4	27
90	Genome-wide association studies and Crohn's disease. Briefings in Functional Genomics, 2011, 10, 71-76.	1.3	41

#	Article	IF	Citations
91	The use of Cyclosporin A in acute steroid-refractory ulcerative colitis: Long term outcomes. Journal of Crohn's and Colitis, 2011, 5, 91-94.	0.6	21
92	Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nature Genetics, 2011, 43, 1066-1073.	9.4	698
93	A rare cause of duodenal stricture. BMJ Case Reports, 2011, 2011, bcr1020103379-bcr1020103379.	0.2	2
94	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics, 2011, 43, 246-252.	9.4	1,201
95	Microscopic colitis. Medicine, 2011, 39, 237-238.	0.2	1
96	New IBD genetics: common pathways with other diseases. Gut, 2011, 60, 1739-1753.	6.1	504
97	Genetic association between NLRP3 variants and CrohnÊ¼s disease does not replicate in a large UK panel. Inflammatory Bowel Diseases, 2011, 17, 1387-1391.	0.9	56
98	Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. Journal of Clinical Investigation, 2011, 121, 4170-4179.	3.9	268
99	Crohn disease: A current perspective on genetics, autophagy and immunity. Autophagy, 2011, 7, 355-374.	4.3	94
100	Proteins Encoded in Genomic Regions Associated with Immune-Mediated Disease Physically Interact and Suggest Underlying Biology. PLoS Genetics, 2011, 7, e1001273.	1.5	450
101	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature, 2010, 464, 713-720.	13.7	737
102	Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nature Genetics, 2010, 42, 436-440.	9.4	581
103	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics, 2010, 42, 1118-1125.	9.4	2,284
104	Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nature Genetics, 2009, 41, 1330-1334.	9.4	483
105	Common variants at five new loci associated with early-onset inflammatory bowel disease. Nature Genetics, 2009, 41, 1335-1340.	9.4	459
106	Investigation of Crohn's Disease Risk Loci in Ulcerative Colitis Further Defines Their Molecular Relationship. Gastroenterology, 2009, 136, 523-529.e3.	0.6	198
107	Symptom classification in irritable bowel syndrome as a guide to treatment. Scandinavian Journal of Gastroenterology, 2009, 44, 796-803.	0.6	8
108	Contribution of TNFSF15 gene variants to CrohnÊ¼s disease susceptibility confirmed in UK population. Inflammatory Bowel Diseases, 2008, 14, 733-737.	0.9	74

#	Article	IF	Citations
109	Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nature Genetics, 2008, 40, 710-712.	9.4	403
110	Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nature Genetics, 2008, 40, 955-962.	9.4	2,422
111	Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut, 2008, 57, 1294-1296.	6.1	118
112	Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy, 2008, 4, 151-175.	4.3	2,064
113	Genetics of inflammatory bowel disease: clues to pathogenesis. British Medical Bulletin, 2008, 87, 17-30.	2.7	51
114	Analysis of Germline GLI1 Variation Implicates Hedgehog Signalling in the Regulation of Intestinal Inflammatory Pathways. PLoS Medicine, 2008, 5, e239.	3.9	63
115	Genome-wide Association Scanning Highlights Two Autophagy Genes,ATG16L1andIRGM, as Being Significantly Associated with Crohnâ€™s Disease. Autophagy, 2007, 3, 649-651.	4.3	132
116	Common pathways in Crohn's disease and other inflammatory diseases revealed by genomics. Gut, 2007, 56, 1489-1492.	6.1	22
117	Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts. Journal of Medical Genetics, 2007, 45, 36-42.	1.5	47
118	Prevalence of CARD15/NOD2 Mutations in Caucasian Healthy People. American Journal of Gastroenterology, 2007, 102, 1259-1267.	0.2	249
119	IL23R Variation Determines Susceptibility But Not Disease Phenotype in Inflammatory Bowel Disease. Gastroenterology, 2007, 132, 1657-1664.	0.6	170
120	Genome-wide association scans identify multiple confirmed susceptibility loci for CrohnÊ¼s disease: Lessons for study design. Inflammatory Bowel Diseases, 2007, 13, 1554-1560.	0.9	14
121	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nature Genetics, 2007, 39, 1329-1337.	9.4	1,298
122	Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nature Genetics, 2007, 39, 830-832.	9.4	1,063
123	Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 2007, 447, 661-678.	13.7	8,895
124	Analysis of the BTNL2 truncating splice site mutation in tuberculosis, leprosy and Crohn's disease. Tissue Antigens, 2007, 69, 236-241.	1.0	30
125	A randomized, doubleâ€blind, placeboâ€controlled trial of lenalidomide in the treatment of moderately severe active Crohnâ€™s disease. Alimentary Pharmacology and Therapeutics, 2007, 26, 421-430.	1.9	30
126	Microscopic colitis. Medicine, 2007, 35, 290-291.	0.2	1

#	Article	IF	Citations
127	Systematic review: the use of mesalazine in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2006, 23, 841-855.	1.9	106
128	Genetic variants in TNF-Î± but not DLG5 are associated with inflammatory bowel disease in a large United Kingdom cohort. Inflammatory Bowel Diseases, 2006, 12, 178-184.	0.9	39
129	Complex insertion/deletion polymorphism in NOD1 (CARD4) is not associated with inflammatory bowel disease susceptibility in East Anglia panel. Inflammatory Bowel Diseases, 2006, 12, 967-971.	0.9	27
130	Evidence for association of OCTN genes and IBD5 with ulcerative colitis. Gut, 2006, 55, 809-814.	6.1	90
131	Human keratin 8 mutations that disturb filament assembly observed in inflammatory bowel disease patients. Journal of Cell Science, 2004, 117, 1989-1999.	1.2	84
132	Molecular genetics of Crohn's disease: recent advances. The European Journal of Surgery, 2003, 164, 887-891.	1.0	3
133	Mobilisation of enterocyte fat stores by oral glucose in humans. Gut, 2003, 52, 834-839.	6.1	131
134	The genetics of inflammatory bowel disease. British Journal of Hospital Medicine, 2003, 64, 599-602.	0.3	3
135	Evidence for inflammatory bowel disease of a susceptibility locus on the X chromosome. Gastroenterology, 2001, 120, 834-840.	0.6	46
136	The management of severe Crohnâ€™s disease. Alimentary Pharmacology and Therapeutics, 2001, 15, 563-573.	1.9	13
137	Ulcerative colitis is more strongly linked to chromosome 12 than Crohn's disease Reply. Gut, 2001, 49, 311-312.	6.1	5
138	Ulcerative colitis and Crohn's disease: molecular genetics and clinical implications. Expert Reviews in Molecular Medicine, 2001, 3, 1-18.	1.6	20
139	Exclusion of Linkage of CrohnÊ¼s Disease to Previously Reported Regions on Chromosomes 12, 7, and 3 in the Belgian Population Indicates Genetic Heterogeneity. Inflammatory Bowel Diseases, 2000, 6, 165-170.	0.9	24
140	The IBD2 Locus Shows Linkage Heterogeneity between Ulcerative Colitis and Crohn Disease. American Journal of Human Genetics, 2000, 67, 1605-1610.	2.6	85
141	Association of ulcerative colitis with rare VNTR alleles of the human intestinal mucin gene, MUC3. Human Molecular Genetics, 1999, 8, 307-311.	1.4	74
142	Contribution of the IL-2 and IL-10 genes to inflammatory bowel disease (IBD) susceptibility. Clinical and Experimental Immunology, 1998, 113, 28-32.	1.1	54
143	Genetics of Inflammatory Bowel Disease. Clinical Science, 1998, 94, 473-478.	1.8	50
144	Genetics of Inflammatory Bowel Disease. A Personal View on Progress and Prospects. Digestive Diseases, 1998, 16, 370-374.	0.8	9

#	Article	IF	Citations
145	Two-Stage Genome-Wide Search in Inflammatory Bowel Disease: Strong Evidence for Susceptibility LOCI on Chromosomes 3, 7 and 12. Clinical Science, 1997, 93, 18P-19P.	0.0	0
146	Mapping susceptibility loci in inflammatory bowel disease: why and how?. Trends in Molecular Medicine, 1997, 3, 546-553.	2.6	7
147	Susceptibility loci in inflammatory bowel disease. Lancet, The, 1996, 348, 1588.	6.3	72
148	Two stage genomeâ€“wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nature Genetics, 1996, 14, 199-202.	9.4	682
149	Cytokine gene polymorphisms in inflammatory bowel disease.. Gut, 1996, 39, 705-710.	6.1	112
150	Geneticsâ€” Clinical and Therapeutic Applications. , 0, , 85-88.		0